We are an early stage enterprise focused on developing innovative products for the treatment of cancer and other life threatening diseases. The following table summarizes our product development pipeline:
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Laurier International Inc
SEC CIK
Corporate docs
IRS number
522286452
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
31 Mar 17
EFFECT
Notice of effectiveness
31 Mar 17
15-12G
Securities registration termination
30 Mar 17
POS AM
Prospectus update (post-effective amendment)
28 Mar 17
POS AM
Prospectus update (post-effective amendment)
28 Mar 17
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 17
DEF 14A
Definitive proxy
18 Nov 16
10-Q
2016 Q3
Quarterly report
14 Nov 16
424B3
Prospectus supplement
4 Nov 16
PRE 14A
Preliminary proxy
4 Nov 16
Latest ownership filings
SC 13G/A
Arno Therapeutics, Inc
3 Jan 18
SC 13G/A
Arno Therapeutics, Inc
14 Feb 17
SC 13G/A
Arno Therapeutics, Inc
14 Feb 17
SC 13G/A
Arno Therapeutics, Inc
14 Feb 17
3
Jonathan J Zucker
9 Jan 17
SC 13D
Arno Therapeutics, Inc
9 Jan 17
SC 13G/A
Arno Therapeutics, Inc
5 Jan 17
4
S DONALD SUSSMAN
3 Jan 17
SC 13D/A
Arno Therapeutics, Inc
3 Jan 17
4
DAVID M TANEN
5 Oct 16
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|